http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b6f9d58a56ec37e8be87df0d05de4ad
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Avorn |
| name | Jerry Avorn |
| given-name | Jerry |
| organization-name | From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (S.P.H., J.M.F., J.A., A.S.K.); and Harvard Center for Bioethics, Harvard Medical School, Boston, MA (S.P.H., A.S.K.). Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston Jerry Avorn ( ), an internist and drug epidemiologist, is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, at Brigham and Women’s Hospital, in Boston, Massachusetts. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. Division of Pharmacoepidemiology and Pharmacoeconomics, Program on Regulation, Therapeutics, and Law, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (K.F.H., J.D.S., K.J.R., R.J.G., J.A., S.S.); and RTI Health Solutions, Research Triangle Park, NC (K.J.R.) Brigham and Women's Hospital, Boston, Massachusetts From Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, and Massachusetts General Hospital, Boston, Massachusetts, and CVS Health, Woonsocket, Rhode Island. From the University of California, Los Angeles, and the Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California; RAND Health, Santa Monica, California and Washington, DC; and Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. From the Division of Pharmacoepidemiology and Pharmacoeconomics (D.H.S., S.S., R.J.G., Y.K., R.L., H.M., J.A.) and Division of Rheumatology, Immunology, and Allergy (D.H.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital Boston Massachusetts Jerry Avorn is a professor of medicine at Harvard Medical School and in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital. From the Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (W.C., A.P., J.A., K.I., W.H.S., N.K.C.); Department of Pharmacy, University of Washington, Seattle (W.C.); CVS Caremark, Woonsocket, RI (T.B.); and CVS Caremark, Northbrook, IL (O.S.M.). From Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Jerry Avorn is a professor of medicine at Harvard Medical School/Brigham and Women’s Hospital. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham & Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts The Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston MA Program on Regulation, Therapeutics, and Law Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women’s Hospital Boston Massachusetts USA; Harvard Medical School Boston Massachusetts USA Dr. Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital — both in Boston. Program on Regulation, Therapeutics and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women’s Hospital Harvard Medical School, Boston, Mass. From the Engelberg Foundation, Palm Beach, FL (A.B.E.); and the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (J.A., A.S.K.). Program On Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Jerry Avorn is a professor of medicine at Harvard Medical School. Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA (J.A.) Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA From the Division of Pharmacoepidemiology and Pharmacoeconomics and the Program on Regulation, Therapeutics, and Law (PORTAL), Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston. From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (K.N.V., J.A., A.S.K.); and the Institute of Law, University of Zurich, Zurich, Switzerland (K.N.V.). From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School — both in Boston. Jerry Avorn is a professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School. From the Department of Medical Oncology, Dana-Farber Cancer Institute, Division of Pharmacoepidemiology and Pharmacoeconomics, and Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA. From Harvard Medical School, Brigham and Women's Hospital, and Harvard School of Public Health, Boston, Massachusetts. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts Jerry Avorn, Brigham and Women’s Hospital and Harvard University. From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics (W.B.F., B.N.R., J.A., A.S.K.) and the Division of Pulmonary and Critical Care Medicine (W.B.F.), Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (W.B.F., B.N.R., J.A., A.S.K.) — both in Boston. Division of Pharmacoeconomics, Dept of Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. From the Department of Medicine, Divisions of Hematology and Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital–Harvard Medical School, Boston, Massachusetts University of California, Los Angeles, Medical Center; Los Angeles, CA 90095 (Ganz)Harvard School of Public Health; Boston, MA 02115 (Kuntz)Brigham and Women's Hospital and Harvard Medical School; Boston, MA 02115 (Benner, Avorn) Jerry Avorn, an internist and drug epidemiologist, is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, at Brigham and Women’s Hospital. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine; Brigham and Women's Hospital and Harvard Medical School; Boston MA USA Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts. Program on Regulation, Therapeutics, and Law, Brigham and Women’s Hospital, Boston, Massachusetts From the Division of Pharmacoepidemiology and Pharmacoeconomics (N.K.C., A.R.P., J.A., W.H.S.) and Division of Cardiology (E.M.A.), Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass. Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts Harvard Medical School; and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts From the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston. From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA From Harvard Medical School and the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital — both in Boston. From Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts. Department of Medicine, Program for the Analysis of Clinical Strategies, Brigham and Women's Hospital, Harvard Medical School, Boston, MA From Cambridge Health Alliance, Somerville (P.A.C.), and Harvard Medical School (P.A.C., J.A., A.S.K.) and the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital (J.A., A.S.K.), Boston — all in Massachusetts. Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (K.I., J.A., W.H.S., N.K.C.); Division of Geriatric Medicine, Department of Primary Care, University of New England College of Osteopathic Medicine, Biddeford, ME (K.I.); Office of Chief Medical Officer (M.T.) and Informatics (C.S.), Aetna, Hartford, CT; and CVS Health, Woonsocket, RI (W.H.S., T.B.). From Harvard Medical School and Brigham & Women's Hospital, Boston, Massachusetts. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusettes From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School. Boston, MA. From Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA. Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, in Boston, Massachusetts. Brigham and Women's Hospital / Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital. Jerry Avorn is an associate professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, in Boston. Health Affairs solicited this response to two papers, by Joel Weissman and colleagues and by Robert Dubois, which accompany this Perspective on the Health Affairs Web site, . Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts From Harvard Medical School and the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital — both in Boston. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. James S. Yeh, MD, MPH, is a Clinical Fellow, Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Kirsten E. Austad, MD, is a Student Fellow, PORTAL, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital a Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. The Program On Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts From the Department of Medicine, Harvard Medical School, and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Mass. Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women's Hospital. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts Harvard Medical School and Brigham and Women’s Hospital in Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, in Boston, Massachusetts Dr. Avorn is a professor of medicine at Harvard Medical School, director of the Harvard Interfaculty Initiative on Medications and Society, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital — all in Boston. From the Program for the Analysis of Clinical Strategies, Gerontology Division, and the Preventive Medicine Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School; and the Claude Pepper Geriatric Research and Training Center, Harvard Medical School, Boston, Mass. Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School Boston MA USA Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. javorn@rics.bwh.harvard.edu Harvard Medical School, Boston 02115, USA; Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston 02120, USA From the Division of Pharmacoepidemiology and Pharmacoeconomics (D.H.S., S.S., R.L., J.A.), Division of Rheumatology, Immunology, and Allergy (D.H.S.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass. Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts (A.S.K., J.A.) From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Dr. Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. The Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School Harvard Medical School and director of the Program for the Analysis of Clinical Strategies at Brigham and Women's Hospital in Boston, where he is an internist and geriatrician. Members of the Expert Panel on Medications and Aging are acknowledged at the end of this essay. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass. Jessica M. Franklin, Niteesh K. Choudhry, Gregory Brill, Michael A. Fischer, Sebastian Schneeweiss, Jerry Avorn, and William H. Shrank are with the Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. Lori Uscher-Pines is with RAND Corporation, Santa Monica, CA. Olga S. Matlin and Troyen A. Brennan are with CVS Caremark, Woonsocket, RI. Center for Healthcare Delivery Sciences (C4HDS), Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Jerry Avorn is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts |
Incoming Links
Total number of triples: 616.